Jacobs Levy Equity Management’s Myriad Genetics MYGN Stock Holding History

Jacobs Levy Equity Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.8M	Sell	1,891,527 -196,965	-9%	-$894K	0.04%	302
2026 Q1	$9.4M	Sell	2,088,492 -181,886	-8%	-$948K	0.04%	316
2025 Q4	$14M	Sell	2,270,378 -172,534	-7%	-$1.25M	0.05%	261
2025 Q3	$17.7M	Buy	2,442,912 +1,492,405	+157%	+$8.86M	0.07%	216
2025 Q2	$5.05M	Buy	+950,507	New	+$5.61M	0.02%	431
2021 Q1	–	Sell	-62,922	Closed	-$1.24M	–	1085
2020 Q4	$1.24M	Sell	62,922 -711,567	-92%	-$11.5M	0.01%	668
2020 Q3	$10.1M	Buy	774,489 +645,116	+499%	+$8.16M	0.1%	210
2020 Q2	$1.47M	Buy	+129,373	New	+$1.84M	0.02%	587
2017 Q3	–	Sell	-65,900	Closed	-$1.7M	–	1001
2017 Q2	$1.7M	Sell	65,900 -219,930	-77%	-$4.67M	0.04%	465
2017 Q1	$5.49M	Buy	285,830 +64,200	+29%	+$1.14M	0.11%	234
2016 Q4	$3.69M	Sell	221,630 -231,996	-51%	-$4.2M	0.07%	299
2016 Q3	$9.34M	Buy	+453,626	New	+$11.5M	0.17%	174

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jacobs Levy Equity Management's MYGN Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Myriad Genetics (MYGN) stake by 9.4% in Q2 2026, selling an estimated $894K and leaving 1,891,527 shares worth $10.8M. The position accounts for 0.04% of the portfolio, ranked #302.

Jacobs Levy Equity Management first reported a position in MYGN in Q3 2016 and has held it in 12 quarters since. The position peaked at $17.7M in Q3 2025. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

Jacobs Levy Equity Management held 1,891,527 shares of Myriad Genetics worth $10.8M as of Q2 2026.
Jacobs Levy Equity Management sold 196,965 Myriad Genetics shares in Q2 2026, an estimated $894K.
Myriad Genetics made up 0.04% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #302 holding.
Jacobs Levy Equity Management first reported a position in Myriad Genetics in Q3 2016 and has held it in 12 quarters since.
Jacobs Levy Equity Management's Myriad Genetics position peaked at $17.7M in Q3 2025.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.